Literature DB >> 9448209

Does intermittent "pulse" topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation?

E Epstein1.   

Abstract

BACKGROUND: Topical 5-fluorouracil (5-FU) is effective in removing actinic keratoses but causes unsightly and painful erosions. Intermittent "pulse" 5-FU therapy has been described as being an effective and comfortable technique for destroying actinic keratoses.
OBJECTIVE: The purpose of this study was to determine the efficacy and cutaneous side effects of intermittent 5-FU therapy.
METHODS: Efficacy of treatment was evaluated by three experienced dermatologists separately comparing randomly arranged before and after photographs. Degree of skin reaction was graded from photographs taken during treatment.
RESULTS: Of 13 patients treated with intermittent 5-FU, two had an excellent result, three a good result, but eight failed to show discernible improvement. Efficacy was linked to the degree of skin irritation.
CONCLUSION: Pulse 5-FU failed to clear actinic keratoses in most patients. Intermittent 5-FU treatment does not dissociate its therapeutic efficacy from its undesirable erosive effects. Pulse therapy is a less intensive way of employing 5-FU and may be of value in patients unwilling to accept the erosions and discomfort that accompany the traditional course of daily 5-FU applications.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9448209     DOI: 10.1016/s0190-9622(98)70542-0

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

1.  pH Responsive 5-Fluorouracil Loaded Biocompatible Nanogels For Topical Chemotherapy of Aggressive Melanoma.

Authors:  Prashant Sahu; Sushil K Kashaw; Samaresh Sau; Varun Kushwah; Sanyog Jain; Ram K Agrawal; Arun K Iyer
Journal:  Colloids Surf B Biointerfaces       Date:  2018-11-10       Impact factor: 5.268

2.  Considerations for use of Fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients.

Authors:  William Philip Werschler
Journal:  J Clin Aesthet Dermatol       Date:  2008-07

3.  Development of novel ionic liquid-based microemulsion formulation for dermal delivery of 5-Fluorouracil.

Authors:  Shishu Goindi; Prabhleen Arora; Neeraj Kumar; Ashana Puri
Journal:  AAPS PharmSciTech       Date:  2014-03-26       Impact factor: 3.246

4.  Current and emerging treatment strategies for the treatment of actinic keratosis.

Authors:  Joshua M Berlin
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-09-17

5.  Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.

Authors:  Kaori Kadoyama; Akiko Kuwahara; Motohiro Yamamori; J B Brown; Toshiyuki Sakaeda; Yasushi Okuno
Journal:  J Exp Clin Cancer Res       Date:  2011-10-05

Review 6.  Cutaneous field cancerization: clinical, histopathological and therapeutic aspects.

Authors:  Luís Antônio Ribeiro Torezan; Cyro Festa-Neto
Journal:  An Bras Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.896

7.  Patient-reported skin reactions to 5% 5-fluorouracil in treatment of actinic keratosis.

Authors:  S Ahmady; E M M Oyen; M H E Jansen; P J Nelemans; J P H M Kessels; N W J Kelleners-Smeets; K Mosterd
Journal:  Br J Dermatol       Date:  2021-08-11       Impact factor: 11.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.